Posted by Michael Wonder on 11 Oct 2021
NICE backs Rinvoq for moderate active RA
11 October 2021 - AbbVie has announced that its oral therapy Rinvoq (upadacitinib) has received a positive recommendation from NICE for the treatment of moderate active rheumatoid arthritis.
Rinvoq with methotrexate has been recommended as a treatment option for adults with moderate active rheumatoid arthritis whose disease has responded inadequately to intensive therapy with two or more conventional disease-modifying anti-rheumatic drugs.
